Between the beginning of January 2020 and June 14, 2023, of the 1,134,641 deaths caused by COVID-19 in the United States, around 307,169 had occurred among those aged 85 years and older. This statistic shows the number of coronavirus disease 2019 (COVID-19) deaths in the U.S. from January 2020 to June 2023, by age.

As of April 26, 2023, around 27 percent of total COVID-19 deaths in the United States have been among adults 85 years and older, despite this age group only accounting for two percent of the U.S. population. This statistic depicts the distribution of total COVID-19 deaths in the United States as of April 26, 2023, by age group.

Background: In clinical trials, several SARS-CoV-2 vaccines were shown to reduce risk of severe COVID-19 illness. Local, population-level, real-world evidence of vaccine effectiveness is accumulating. We assessed vaccine effectiveness for community-dwelling New York City (NYC) residents using a quasi-experimental, regression discontinuity design, leveraging a period (January 12-March 9, 2021) when ≥ 65-year-olds were vaccine-eligible but younger persons, excluding essential workers, were not. Methods: We constructed segmented, negative binomial regression models of age-specific COVID-19 hospitalization rates among 45-84-year-old NYC residents during a post-vaccination program implementation period (February 21-April 17, 2021), with a discontinuity at age 65 years. The relationship between age and hospitalization rates in an unvaccinated population was incorporated using a pre-implementation period (December 20, 2020-February 13, 2021). We calculated the rate ratio (RR) and 95% confidence interval (CI) for the interaction between implementation period (pre or post) and age-based eligibility (45-64 or 65-84 years). Analyses were stratified by race/ethnicity and borough of residence. Similar analyses were conducted for COVID-19 deaths. Results: Hospitalization rates among 65-84-year-olds decreased from pre- to post-implementation periods (RR 0.85, 95% CI: 0.74-0.97), controlling for trends among 45-64-year-olds. Accordingly, an estimated 721 (95% CI: 126-1,241) hospitalizations were averted. Residents just above the eligibility threshold (65-66-year-olds) had lower hospitalization rates than those below (63-64-year-olds). Racial/ethnic groups and boroughs with higher vaccine coverage generally experienced greater reductions in RR point estimates. Uncertainty was greater for the decrease in COVID-19 death rates (RR 0.85, 95% CI: 0.66-1.10). Conclusion: The vaccination program in NYC reduced COVID-19 hospitalizations among the initially age-eligible ≥ 65-year-old population by approximately 15% in the first eight weeks. The real-world evidence of vaccine effectiveness makes it more imperative to improve vaccine access and uptake to reduce inequities in COVID-19 outcomes.

NOTE: This dataset has been retired and marked as historical-only.

Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age.

Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine.

Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS).

Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death.

Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test.

CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset.

Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000.

Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people.

Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population.

Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to COVID-19, see https://data.cityofchic

Death rate and survival probability of COVID-19 patients hospitalized at Bokoji Hospital treatment centre, Ethiopia, 2021.

BackgroundWe aimed to determine the trend of TB-related deaths during the COVID-19 pandemic.MethodsTB-related mortality data of decedents aged ≥25 years from 2006 to 2021 were analyzed. Excess deaths were estimated by determining the difference between observed and projected mortality rates during the pandemic.ResultsA total of 18,628 TB-related deaths were documented from 2006 to 2021. TB-related age-standardized mortality rates (ASMRs) were 0.51 in 2020 and 0.52 in 2021, corresponding to an excess mortality of 10.22 and 9.19%, respectively. Female patients with TB demonstrated a higher relative increase in mortality (26.33 vs. 2.17% in 2020; 21.48 vs. 3.23% in 2021) when compared to male. Female aged 45–64 years old showed a surge in mortality, with an annual percent change (APC) of −2.2% pre-pandemic to 22.8% (95% CI: −1.7 to 68.7%) during the pandemic, corresponding to excess mortalities of 62.165 and 99.16% in 2020 and 2021, respectively; these excess mortality rates were higher than those observed in the overall female population ages 45–64 years in 2020 (17.53%) and 2021 (33.79%).ConclusionThe steady decline in TB-related mortality in the United States has been reversed by COVID-19. Female with TB were disproportionately affected by the pandemic.

The death rate in New York City for adults aged 75 years and older was around 4,135 per 100,000 people as of December 22, 2022. The risk of developing more severe illness from COVID-19 increases with age, and the virus also poses a particular threat to people with underlying health conditions.

What is the death toll in NYC? The first coronavirus-related death in New York City was recorded on March 11, 2020. Since then, the total number of confirmed deaths has reached 37,452 while there have been 2.6 million positive tests for the disease. The number of daily new deaths in New York City has fallen sharply since nearly 600 residents lost their lives on April 7, 2020. A significant number of fatalities across New York State have been linked to long-term care facilities that provide support to vulnerable elderly adults and individuals with physical disabilities.

The impact on the counties of New York State Nearly every county in the state of New York has recorded at least one death due to the coronavirus. Outside of New York City, the counties of Nassau, Suffolk, and Westchester have confirmed over 11,500 deaths between them. When analyzing the ratio of deaths to county population, Rockland had one of the highest COVID-19 death rates in New York State in 2021. The county, which has approximately 325,700 residents, had a death rate of around 29 per 10,000 people in April 2021.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

As of February 4, 2022, in the age group 75 to 84 years old COVID-19 was involved in the deaths of 32,780 males and 23,390 females in the United Kingdom. Furthermore, since the pandemic started over 72 thousand deaths in the UK among those aged 85 years and above involved COVID-19. For further information about the COVID-19 pandemic, please visit our dedicated Facts and Figures page.

In the United States in 2021, the death rate was highest among those aged 85 and over, with about 17,190.5 men and 14,914.5 women per 100,000 of the population passing away. For all ages, the death rate was at 1,118.2 per 100,000 of the population for males, and 970.8 per 100,000 of the population for women. The death rate Death rates generally are counted as the number of deaths per 1,000 or 100,000 of the population and include both deaths of natural and unnatural causes. The death rate in the United States had pretty much held steady since 1990 until it started to increase over the last decade, with the highest death rates recorded in recent years. While the birth rate in the United States has been decreasing, it is still currently higher than the death rate. Causes of death There are a myriad number of causes of death in the United States, but the most recent data shows the top three leading causes of death to be heart disease, cancers, and accidents. Heart disease was also the leading cause of death worldwide.

Seroprevalence and infection fatality rate (IFR) estimates in New York City for five age classes, using confirmed COVID-19 deaths (excluding probable deaths).

As of May 2, 2023, of 34,206 COVID-19 cases deceased in Canada, around 4,058 were aged 60 to 69 years. This statistic shows the number of COVID-19 deaths in Canada as of May 2, 2023, by age.

Sociodemographic characteristics and treatment outcome status of hospitalized patients with COVID-19 to Bokoji Hospital treatment centre, 2021.

The coronavirus (COVID-19) has led to over 183,000 deaths in Germany, as of 2024. When looking at the distribution of deaths by age, based on the figures currently available, most death occurred in the age group 80 years and older at approximately 118,938 deaths.

BackgroundThe COVID-19 pandemic has stretched healthcare resources thin and led to significant morbidity and mortality. There have been no studies utilizing national data to investigate the role of cardiac risk factors on outcomes of COVID hospitalizations. The aim of this study was to examine the effect of cardiac multimorbidity on healthcare utilization and outcomes among COVID hospitalizations during the first year of the pandemic.MethodsUsing the national inpatient sample (NIS), we identified all adult hospital admissions with a primary diagnosis of COVID in 2020, using International Classification of Diseases, Tenth Revision, Clinical Modification codes (ICD010-CM). Coronary artery disease, diabetes mellitus, heart failure, peripheral vascular disease, previous stroke, and atrial fibrillation were then identified as cardiac comorbidities using ICD-10-CM codes. Multivariable logistic regression was used to evaluate the effect of cardiac multimorbidity on mortality and mechanical ventilation.ResultsWe identified 1,005,040 primary COVID admissions in 2020. Of these admissions, 216,545 (20.6%) had CAD, 413,195 (39.4%) had DM, 176,780 (16.8%) had HF, 159,700 (15.2%) had AF, 30735 (2.9%) had PVD, and 25,155 (2.4%) had a previous stroke. When stratified by number of comorbidities, 428390 (40.8%) had 0 comorbidities, 354960 (33.8%) had 1, 161225 (15.4%) had 2, and 105465 (10.0%) had 3+ comorbidities. COVID hospitalizations with higher cardiac multimorbidity had higher mortality rates (p